In this video from the Lung Institute, you can listen to Dr. Jack Coleman, Jr., M.D, the medical director of the Lung Institute’s clinic in Nashville, on Dr. Michael Smith’s RadioMD show – Healthy Talk. In this interview, Dr. Coleman talks about the…
Meet Dr. Charles Chan, a researcher who focuses on IPF. In this video, shared by The Canadian Pulmonary Fibrosis Foundation, discover more as he speaks about how he truly believes the future for IPF patients is improving and he also shares some opinions and facts on how to improve the…
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated that the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to…
Staying active and exercising may sometimes be unpleasant, but has a lot of positive effects and is highly encouraged in patients with idiopathic pulmonary fibrosis (IPF). Here are some tips on how you can manage your fitness and how you can measure it. “Exercise capacity can be clinically…
Pulmonary fibrosis (PF) is a respiratory condition that causes the formation of scar tissue in the lungs. It is a progressive disease and can take years to advance. Due to the thickening lung tissue, the lungs face difficulties in properly transporting oxygen to the bloodstream and…
A study from the University of Madras, India, showed that celastrol — a component of an extract from the Thunder God Vine root — was able to reduce inflammation, collagen deposition, and alveolar damage in a rat model of pulmonary fibrosis (PF). The effects were likely the result of…
The heart’s right ventricle in systemic sclerosis patients is impaired when compared to people without the disease, according to a study titled “Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis,” published in the journal Rheumatology. Patients with systemic…
This video created by King’s College Hospital, London, explains the advantages and impact of pulmonary rehabilitation for patients with lung diseases such as pulmonary fibrosis (PF), encouraging them to enroll in rehabilitation programmes. Learn more and keep updated on all the latest PF news here: http://bit.ly/1VElTQA…
Pulmonary fibrosis (PF) is a respiratory disease characterized by the presence of scarred tissue in the lungs. The disease starts to cause thickening and stiffening of the tissue, which ends up turning into fibrosis and causing difficulties for the lungs to properly transport the oxygen into…
Last week’s hot topic on pulmonary fibrosis was Experimental Pulmonary Fibrosis Therapy, GR-MD-02, Granted U.S. Patent Allowance and was written by Carolina Henriques. This article is focused on Galectin Therapeutics, Inc‘s, announcement that it has received a Notice of Allowance from the U.S. Patent and Trademark Office…
Get regular updates to your inbox.
